Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GATA2 antisense RNA 1 (GATA2-AS1)
- Target
- GATA2-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Non-coding RNA
01
Overview
GATA2 antisense RNA 1 (GATA2-AS1) is a long non-coding RNA transcribed antisense to the GATA2 gene, with its transcription start site located ~1.2kb from GATA2. It is highly expressed in endothelial cells and several highly vascularized tissues (lung, placenta, kidney), and is also upregulated in various cancer cell types, including colorectal and non-small cell lung cancer. GATA2-AS1 functions in regulatory feedback loops with the protein-coding GATA2 gene, stabilizing GATA2 mRNA and being transcriptionally activated by GATA2, thereby influencing critical pathways in cancer progression, especially epithelial-mesenchymal transition, migration, invasion, and maintenance of cancer stemness. In the endothelium, GATA2-AS1 coordinates metabolic adaptation and angiogenesis, especially in hypoxic conditions, by maintaining expression of glycolytic genes. While emerging evidence points to its role as a potential therapeutic target and biomarker in cancer and vascular biology, no approved drugs target this RNA directly.
- Other names
- GATA2-AS1GATA2 Antisense RNA 1NR_125398.1 (NCBI RefSeq)ENSG00000244300.2 (Gencode Gene)
02
Mechanism of action
Not applicable (no approved drugs or tool compounds directly target GATA2-AS1 to date)
03
Biological functions
Regulation of gene expression (post-transcriptional and transcriptional)Maintenance of glycolytic pathway genes (especially under hypoxia)Promotion of epithelial-mesenchymal transition (EMT)Modulation of cell proliferation, migration, invasion, and cancer stemnessRegulation of endothelial angiogenic response
04
Disease associations
Cancer (notably colorectal cancer and non-small cell lung cancer)TumorigenesisEndothelial dysfunction/hypoxia-associated disorders (inferred from expression profile)
05
Safety considerations
Not formally characterized for therapeutic targeting; challenges may include specificity of RNA-based interventions and off-target effects common with lncRNA-targeted therapies
06
Interacting drugs
None reported in current literature or databases as of this review
07
Biomarkers
Elevated GATA2-AS1 expression for colorectal cancer (potential prognostic/diagnostic marker)
Beyond the preview
Go deeper on GATA2 antisense RNA 1 (GATA2-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GATA2 antisense RNA 1 (GATA2-AS1).